Takeda Pharmaceuticals Articles
Millennium is first industry partner in collaboration to advance personalized medicine for multiple myeloma
2 October 2011
Orexigen and FDA find way forward for obesity drug Contrave
21 September 2011
New twist in diabetes drugs could reduce life-threatening side effects
12 September 2011
Takeda’s Mepact backed by UK’s NICE for osteosarcoma, after previous negative opinion
7 September 2011
Speculation Takeda is looking to buy India’s Cipla or Lupin; Sanofi acquires OTC firm
25 August 2011
US FDA sets PDUFA action dates for Bydureon and peginesatide
12 August 2011
Amylin and Takeda drop combo obesity drug development
8 August 2011
EU Commission OKs Takeda’s acquisition of Nycomed
3 August 2011
First-quarter FY 2012 net profit at Takeda jumps 18%, while that at Daiichi Sankyo slumps 23.5%
2 August 2011
Takeda refiles NDAs with US FDA for diabetes drug alogliptin and combo with pioglitazone
27 July 2011
More Japanese drug OKs: GSK’s Rotarix and Lamictal; Takeda’s Liovel and new use for Eisai/Abbott’s Humira
4 July 2011
EMA recommends Boehringer/Lilly’s Tradjenta, Novartis’ Votubia and Sigma-Tau’s Eurartesim; updates on pioglitazone
27 June 2011
Takeda denies it is in talks to buy Nycomed
13 May 2011
Takeda fiscal 2011 sales dip and earnings plunge
13 May 2011
Nycomed targeted for takeover by Takeda; reports
12 May 2011
Takeda says Edarbi now available in USA; progresses pancreatic cancer drug into Ph III
18 April 2011
Takeda links with Dainippon Sumitomo on two licensing deals; makes European management appointments
1 April 2011
Takeda and Amgen NSCLC drug motesanib fails in Ph III
31 March 2011
Alnylam earns $10 million from Takeda alliance
29 March 2011
Takeda in-licenses schizophrenia drug candidates from Intra-Cellular for up to $750 million
3 March 2011
US FDA clears Takeda’s Edarbi for hypertension and grants full approval for GSK’s Promacta
28 February 2011
Takeda files US NDA for combo hypertension drug; gets new indications for Nesina in Japan
25 February 2011
Takeda recalls anti-inflammatory Dasen in Japan due to efficacy
22 February 2011
Takeda settles Actos patent law suits with Mylan, Watson and Ranbaxy, as well as Teva and others
22 December 2010
First new obesity drug in over a decade could come to US market as FDA panel backs Orexigen’s Contrave
8 December 2010
Takeda in schizophrenia research alliance with Envoy Thera
11 October 2010
UK’s NICE rejects use of Takeda’s Mepact based on cost, denying children life saving treatment for bone cancer
8 October 2010
Seattle's lead drug Brentuximab performs in Hodgkin's lymphoma trial
29 September 2010
Preliminary safety data relating to bladder cancer risk of Takeda’s Actos under review by US FDA; Actelion subpoenaed over Tracleer marketing
20 September 2010
Orexigen Therapeutics in $1 billion-plus deal with Japan’s Takeda for obesity drug Contrave in North America
3 September 2010
New study finds little difference in cardiac risk for GlaxoSmithKline’s Avandia and Takeda’s Actos
25 August 2010
Takeda reports sharp downturn if 1st-qtr FY2011 profits, as sales fall 6.4%; appoints international VPs
2 August 2010
Takeda receives pricing approval of Nesina in Japan, triggering milestone for Furiex Pharma
14 June 2010
Two of Japan’s top drugmakers - Takeda and Astellas - expect profits decline as patent expiries bite
13 May 2010
Takeda files NDA for azilsartan medoxomil in USA, settles Actos patent disputes; Actavis debuts generic Flomax
29 April 2010
Japan’s Takeda gets five new products approved on home market, and partner Amgen reveals strong results with Vectibix
19 April 2010
Majority of researchers supporting GlaxoSmithKline’s Avandia “had ties to the firm;” Takeda pulls SR-Competact MAA
22 March 2010
Takeda gets rights to Seattle’s brentuximab and picks Pfizer for Actos in China; and Amgen licenses diabetes drug
15 December 2009
Teva files suit against Momenta/Sandoz over Copaxone, OK for generic Prevacid in USA for Teva and Mylan
11 November 2009
Takeda sets up new subsidiaries to expand its operations in Mexico, Turkey and five other countries in Europe
1 October 2009
Record sales balanced by costs for Takeda
27 May 2009
Takeda agrees to buy IDM Pharma for $75M
19 May 2009
Novartis gets FDA approval for OTC Prevacid
15 May 2009
Takeda's Kapidex DR launches in USA
2 March 2009
Takeda/Teijin gain US OK for new gout drug
23 February 2009
Japan stock market week to Oct 6, 2008
13 October 2008
Takeda subsid appoints new president and CSO
2 June 2008
Abbott reports 35% rise in earnings
28 April 2008
Japan stock market week to March 24, 2008
31 March 2008
Faust signs contract with Takeda
14 January 2008
EU regulators accept SNT-MC17 for review
3 September 2007
GSK: new data will support Avandia safety
4 June 2007
Lilly's 1st-qtr 2007 earnings drop 39%
23 April 2007
Takeda submits MAA application for ramelteon
26 March 2007
Mehmood Khan named president of Takeda GR&DC
29 January 2007
Japan's generic drugs market expected to grow 8.8% from 2006 to 2008
27 November 2006
Takeda gets attorney's fees in Actos patent case
2 October 2006
Takeda's sales reach $2.9B for 1st-qtr 2007
14 August 2006
Takeda's Duetact get FDA OK for diabetes
7 August 2006
Japan stock market week to June 26, 2006
3 July 2006
Japan stock market week to June 19, 2006
26 June 2006
Rozerem shows efficacy as transient insomnia drug
26 June 2006
Japan stock market week to May 1, 2006
8 May 2006
Santhera begins Ph III trial of FRDA drug SNT-MC17
19 December 2005
FDA approves Takeda's ACTOplus met
5 September 2005
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
